Gland Pharma (NSE:GLAND) Moat Score: 0/10 (As of Jul. 01, 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
83 GF Score
Price ₹2,495.00
GF Value ₹2,129.62
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Gland Pharma Moat Score?

Gland Pharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Gland Pharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Gland Pharma might have No Moat - No discernible moat.

Gland Pharma  (NSE:GLAND) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Gland Pharma Moat Score Related Terms

NSE:GLAND
83GF Score
Gland Pharma Ltd NSE:GLAND
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,495.00 is trading 17.2% above its estimated GF Value™ of ₹2,129.62. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Moat Score: 0
  • GF Value™: ₹2,129.62 vs. price of ₹2,495.00 (17.2% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score

Get the complete analysis for NSE:GLAND

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,495.00
Price
₹2,129.62
GF Value